Schonfeld Strategic Advisors LLC Tricida, Inc. Transaction History

Schonfeld Strategic Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $622,081 - $994,160	73,100 Added 96.69%	148,700 $1.56 Million
Q2 2022 Aug 15, 2022	BUY	$7.31 - $11.85 $201,756 - $327,060	27,600 Added 57.5%	75,600 $731,000
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $186,690 - $270,002	25,400 Added 112.39%	48,000 $394,000
Q3 2021 Nov 16, 2021	SELL	$3.56 - $4.64 $2,136 - $2,784	-600 Reduced 2.59%	22,600 $105,000
Q2 2021 Aug 16, 2021	BUY	$3.95 - $5.41 $16,195 - $22,181	4,100 Added 21.47%	23,200 $101,000
Q1 2021 May 17, 2021	BUY	$4.52 - $7.8 $14,915 - $25,740	3,300 Added 20.89%	19,100 $101,000
Q4 2020 Feb 16, 2021	BUY	$4.37 - $9.46 $69,046 - $149,468	15,800 New	15,800 $111,000
Q3 2020 Nov 16, 2020	SELL	$8.56 - $26.93 $149,817 - $471,328	-17,502 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$21.21 - $31.55 $371,217 - $552,188	17,502 New	17,502 $481,000
Q1 2019 May 15, 2019	SELL	$19.96 - $38.62 $307,863 - $595,674	-15,424 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$23.57 - $32.33 $94,845 - $130,095	4,024 Added 35.3%	15,424 $364,000
Q3 2018 Nov 14, 2018	BUY	$22.5 - $39.35 $256,500 - $448,590	11,400 New	11,400 $348,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.